---
title: "\"Performance\" VENUS MEDTECH's annual loss narrowed to 408 million RMB, no dividend declared"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/281293184.md"
description: "VENUS MEDTECH announced its full-year results for the year ended December last year, with a revenue of RMB 307 million, a year-on-year decrease of 34.8%. The loss narrowed to RMB 408 million, compared to a loss of RMB 714 million in the same period last year; the loss per share was RMB 0.93. No dividend was declared"
datetime: "2026-04-01T02:26:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281293184.md)
  - [en](https://longbridge.com/en/news/281293184.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281293184.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/281293184.md) | [English](https://longbridge.com/en/news/281293184.md)


# "Performance" VENUS MEDTECH's annual loss narrowed to 408 million RMB, no dividend declared

VENUS MEDTECH (02500.HK) announced its full-year results for the year ending last December, with revenue of RMB 307 million, a year-on-year decrease of 34.8%. Losses narrowed to RMB 408 million, compared to a loss of RMB 714 million in the same period last year; loss per share was RMB 0.93. No dividend was declared

### 相關股票

- [VENUS MEDTECH-B (02500.HK)](https://longbridge.com/zh-HK/quote/02500.HK.md)

## 相關資訊與研究

- [ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma](https://longbridge.com/zh-HK/news/281068292.md)
- [11:33 ETFitness, Health and Wellness Experts Team Up to 'Get Fit for No Kid Hungry' with New On-Demand Initiative](https://longbridge.com/zh-HK/news/281213207.md)
- [Assessing Securitas (OM:SECU B) Valuation After Recent Share Price Volatility](https://longbridge.com/zh-HK/news/280905109.md)
- [08:38 ETAmericaWest Medical Transportation Launches SMART on FHIR App, Now Available in the Epic Showroom and on VectorCare's Marketplace](https://longbridge.com/zh-HK/news/281021636.md)
- [Jenscare’s iJensRobo Heart Valve Robot Completes First Clinical Study in Hong Kong](https://longbridge.com/zh-HK/news/280936540.md)